Mesoblast (NasdaqGS:MESO) H1 2026 Earnings call February 26, 2026 05:00 PM ET Company ParticipantsJames O'Brien - CFOMarcelo Santoro - Chief Commercial OfficerPaul Hughes - Head of Corporate Finance and Investor RelationsSilviu Itescu - CFO and Managing DirectorConference Call ParticipantsEdward Tenthoff - Managing Director and Senior Research AnalystMadeleine Williams - Equity Research AnalystMichael Okunewitch - Biotechnology Senior Research AnalystOlivia Brayer - Director and Senior Biotech AnalystOperat ...

Organogenesis (NasdaqCM:ORGO) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Company ParticipantsDave Francisco - CFOGary S. Gillheeney, Senior - President, CEO, and Chair of the BoardNone - Company RepresentativeOperatorWelcome, ladies and gentlemen, to the fourth quarter and full year 2025 earnings conference call for Organogenesis Holdings, Inc. At this time, all participants have been placed in listen-only mode. Please note that this conference call is being recorded and that the recording will be ...

智通财经APP讯，和元生物(688238.SH)发布2025年度业绩快报，报告期内，公司实现营业收入2.68亿 元，较上年同期增长7.86%;实现归属于母公司所有者的净亏损2.21亿元。 报告期内，国内生物医药领域机遇与挑战交织并存，呈现出多元化发展与市场激烈竞争的复杂态势，公 司坚持聚焦细胞和基因治疗CRO/CDMO主营业务，并借助国家及行业发展政策，积极战略布局再生医 学应用领域。在运营策略上，公司报告期内侧重点在加强客户资源储备、提升品牌影响力以及推动行业 发展等方面，以练好内功、升级运营管理能力、推动降本增效为主要绩效目标，逐步提升管理质量和运 营效率，为业务后续发展打下坚实基础。 ...

格隆汇2月26日丨和元生物(688238.SH)公布2025年度业绩快报，报告期内，公司实现营业收入26,766.34 万元，较上年同期增长7.86%；实现归属于母公司所有者的净利润-22,071.57万元，较上年同期减少亏损 10,109.73万元；实现归属于母公司所有者的扣除非经常性损益的净利润-23,202.12万元，较上年同期减 少亏损10,389.12万元。 报告期内，国内生物医药领域机遇与挑战交织并存，呈现出多元化发展与市场激烈竞争的复杂态势，公 司坚持聚焦细胞和基因治疗CRO/CDMO主营业务，并借助国家及行业发展政策，积极战略布局再生医 学应用领域。在运营策略上，公司报告期内侧重点在加强客户资源储备、提升品牌影响力以及推动行业 发展等方面，以练好内功、升级运营管理能力、推动降本增效为主要绩效目标，逐步提升管理质量和运 营效率，为业务后续发展打下坚实基础。 ...

和元生物公告，公司2025年实现营业收入26,766.34万元，较上年同期增长7.86%；实现归属于母公司所 有者的净利润-22,071.57万元，较上年同期减少亏损10,109.73万元；实现归属于母公司所有者的扣除非 经常性损益的净利润-23,202.12万元，较上年同期减少亏损10,389.12万元。报告期内，国内生物医药领 域机遇与挑战交织并存，呈现出多元化发展与市场激烈竞争的复杂态势，公司坚持聚焦细胞和基因治疗 CRO/CDMO主营业务，并借助国家及行业发展政策，积极战略布局再生医学应用领域。 ...

AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50.00%. A quarter ago, it was expected that this regenerative medicine company would post earnings of $0.09 per share when it actually produced earnings of $0.12, delivering a surprise of +33.33%.Over the last four quarter ...

全球首批基于干细胞技术的治疗产品即将上市，有望功能性治愈帕金森及心衰等过去难以治疗的重大疾 病。 以心衰为例，过去心肌坏死意味着心脏功能永久"打折"，患者只能靠吃药、做手术勉强维持。而借助干 细胞技术，"心肌再生"已经成为现实。 干细胞疗法就好比"给心脏种下再生的种子"。心肌细胞补片就像一块"心肌创可贴"，贴在受损心脏上， 可以模拟心肌的自然生长环境，让"种子"存活率更高，并且这种补片还能分泌有益物质，帮助血管再 生，融入心脏一起跳动。更重要的是，这些干细胞能从患者自己身上获取，因此不会出现"排异反应"， 未来每个人都可能有专属的"心肌修复种子"。 尽管日本相关疗法即将上市，但干细胞疗法仍然面临成本高昂的挑战。培育干细胞、研发心脏补片的成 本很高，并且新技术使用的监管政策及伦理标准仍在不断完善中。 在我国，包括干细胞治疗技术在内的再生医学正在快速发展。去年9月公布的《生物医学新技术临床研 究和临床转化应用管理条例》也将于今年2026年5月1日起施行，该条例给予包括干细胞在内的生物医学 新技术以清晰的转化应用路径，相关细则也将进一步完善。 给心脏种下"再生"的种子 近日，日本厚生劳动省支持了两款干细胞治疗产品的 ...

阿通社2月9日消息，第四届迪拜干细胞大会在迪拜闭幕，共吸引了500余名医生和研究人员、26位 国际专家参会。会议重点讨论了干细胞监管、临床转化及再生医学前沿应用，涵盖慢性病治疗、CAR-T 疗法、类器官研究和AI成像等方向。大会期间还举办多场实践工作坊，推动科研成果向临床应用转 化。主办方表示，大会已成为连接科研创新与医疗实践的重要国际平台，进一步提升了迪拜在再生医学 领域的区域影响力。 （原标题：第四届迪拜干细胞大会闭幕） ...

Group 1 - The core viewpoint of the news is that Yiqiao Shenzhou (301047) is participating in the 15th Cell Biology Industry Conference, which focuses on cell therapy and regenerative medicine, scheduled for March 5-6, 2026, in Chengdu [1] - The number of shareholders in Yiqiao Shenzhou increased by 2.44% as of February 9, 2026, indicating a change in investor interest [1] Group 2 - Over the past 7 days (February 6 to 11, 2026), Yiqiao Shenzhou's stock price fluctuated within a range of 0.34%, with a high of 74.77 yuan and a low of 73.14 yuan, showing a volatile trend [2] - On February 11, 2026, there was a net outflow of 1.1075 million yuan in main funds, while retail investor activity remained high [2] Group 3 - As of February 12, 2026, institutions set a comprehensive target price for Yiqiao Shenzhou at 78.00 yuan, indicating limited upside potential compared to the latest stock price [3] - The forecast for net profit in 2025 is expected to grow by 18.10%, while revenue for 2026 is projected to increase by 9.06% [3] - Market sentiment is neutral, and the frequency of institutional research is relatively low [3]

Core Viewpoint - The company, Dajia Weikang (301126), is expected to report a loss in 2025 due to intensified industry competition and goodwill impairment, while its major shareholder plans to reduce its stake by up to 3% [1][2][3]. Group 1: Financial Performance - The company forecasts its 2025 revenue to be between 5.5 billion to 6 billion yuan, representing a year-on-year growth of 5.09% to 14.65% [2]. - The anticipated net loss for 2025 is projected to be between 250 million to 300 million yuan, primarily due to increased industry competition and goodwill impairment [2]. Group 2: Shareholder Actions - The controlling shareholder's concerted action party, Changsha Tongjia Investment Management Partnership, plans to reduce its holdings by no more than 6.16 million shares, which accounts for 3% of the total share capital, between March 10 and June 9, 2026 [3]. Group 3: Product Development Progress - The company is collaborating with Hunan University and other institutions to establish a clinical research center in the field of regenerative medicine, aiming to promote technology transfer [4]. - Ongoing product developments include the sodium salt of sacubitril/valsartan, which is in the technical review stage, and the application for ezetimibe/atorvastatin calcium tablets is being prepared, which may impact future business layout [4].